<seo title="Incyte" metakeywords="incyte biopharmaceutical company,incyte partnerships biopharmaceutical,incyte biopharmaceutical,incyte incyte biopharmaceutical" metadescription="Incyte is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel small molecule drugs to treat serious diseases."/>
===Introduction to Incyte===

Incyte is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel small molecule drugs to treat serious diseases. The company was founded in 1991 and is headquartered in Wilmington, Delaware. Incyte has a broad portfolio of products and services, including treatments for cancer, inflammation, and autoimmune diseases. Incyte is a publicly traded company on the NASDAQ stock exchange and has a [[Market Capitalization|market capitalization]] of over $20 billion.
===History of Incyte===

Incyte was founded in 1991 by Paul A. Friedman and Charles B. Sanders. The company was initially focused on the discovery and development of small molecule drugs to treat cancer. Incyte’s first product, Jakafi, was approved by the FDA in 2011 and is used to treat myelofibrosis, a rare blood disorder. Since then, Incyte has continued to expand its product portfolio and has developed treatments for a variety of diseases, including cancer, inflammation, and autoimmune diseases.
===Financial Performance of Incyte===

Incyte has experienced strong [[Financial Performance|financial performance]] in recent years. In 2020, the company reported total revenue of $3.3 billion, an increase of 11% from the previous year. Incyte’s [[Net Income|net income]] for 2020 was $1.2 billion, an increase of 17% from the previous year. Incyte’s stock price has also increased significantly over the past year, rising from $50 per share in January 2020 to over $90 per share in January 2021.
===Incyte’s Business Model===

Incyte’s business model is focused on the discovery, development, and commercialization of novel small molecule drugs to treat serious diseases. The company has a broad portfolio of products and services, including treatments for cancer, inflammation, and autoimmune diseases. Incyte’s products are sold through a variety of channels, including direct sales, wholesalers, and specialty pharmacies. In addition, Incyte has partnerships with other biopharmaceutical companies to develop and commercialize its products.
===Incyte’s Products and Services===

Incyte has a broad portfolio of products and services, including treatments for cancer, inflammation, and autoimmune diseases. The company’s most successful product is Jakafi, which is used to treat myelofibrosis. In addition, Incyte has developed treatments for a variety of other diseases, including breast cancer, leukemia, and psoriasis. Incyte also offers a range of services, including clinical development, regulatory affairs, and commercialization.
===Incyte’s Competitive Advantage===

Incyte has a number of competitive advantages that have enabled the company to achieve strong financial performance. The company has a broad portfolio of products and services, including treatments for cancer, inflammation, and autoimmune diseases. In addition, Incyte has a strong research and development pipeline, which has enabled the company to develop a number of novel treatments. Finally, Incyte has strong partnerships with